enGene Holdings Inc. Common Stock Cash Flow Conversion Efficiency
enGene Holdings Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, enGene Holdings Inc. Common Stock (ENGN) has a cash flow conversion efficiency ratio of -0.082x as of July 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.95 Million) by net assets ($230.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of enGene Holdings Inc. Common Stock (2021–2025)
Cash flow conversion efficiency of enGene Holdings Inc. Common Stock from 2021 to 2025. This chart illustrates how enGene Holdings Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of enGene Holdings Inc. Common Stock for real-time trading data and today's change.
enGene Holdings Inc. Common Stock Cash Flow Conversion Ratio Explained
enGene Holdings Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
enGene Holdings Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of enGene Holdings Inc. Common Stock ranked by their cash flow conversion efficiency. Also see ENGN market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ADDvise Group B
ST:ADDV-B
|
0.032x |
|
Icon Group
TA:ICON
|
-0.040x |
|
Monte Carlo Fashions Limited
NSE:MONTECARLO
|
-0.204x |
|
DAE-IL Corporation
KO:092200
|
0.052x |
|
Cape Industries Ltd
KQ:064820
|
0.161x |
|
Bank Negara Indonesia Tbk
JK:BBNI
|
0.385x |
|
Rentokil Initial PLC
LSE:RTO
|
0.077x |
|
Kuang Hong Arts Management
TWO:6596
|
-0.016x |
Annual Cash Flow Conversion Efficiency for enGene Holdings Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of enGene Holdings Inc. Common Stock from 2021 to 2025. Review enGene Holdings Inc. Common Stock free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-10-31 | $167.71 Million | $-99.24 Million | -0.592x | -234.11% |
| 2024-10-31 | $272.61 Million | $-48.28 Million | -0.177x | +48.12% |
| 2023-10-31 | $72.49 Million | $-24.74 Million | -0.341x | -147.25% |
| 2022-10-31 | $127.42 Million | $-17.59 Million | -0.138x | -10.03% |
| 2021-10-31 | $127.39 Million | $-15.98 Million | -0.125x | -- |
About enGene Holdings Inc. Common Stock
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. T… Read more